The FDA is expected to make a decision on whether to approve Merck & Co. (NYSE:MRK) two-drug, once-daily therapy for hepatitis C in January, and if the agency gives Merck & Co. the green light, then it could significantly impact Gilead Sciences’ (NASDAQ:GILD) market share in the most common variation of this disease.
